Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers

M. Meyer, K. M. Beeh, J. Beier, E. Aydt, R. Zahlten, B. Jilma, G. Wolff (Berlin, Wiesbaden, Germany; Vienna, Austria)

Source: Annual Congress 2006 - COPD and inflammation
Session: COPD and inflammation
Session type: Oral Presentation
Number: 1995
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Meyer, K. M. Beeh, J. Beier, E. Aydt, R. Zahlten, B. Jilma, G. Wolff (Berlin, Wiesbaden, Germany; Vienna, Austria). Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers. Eur Respir J 2006; 28: Suppl. 50, 1995

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009


Safety and tolerability of single doses of AZD5069 in healthy volunteers
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics
Source: International Congress 2017 – From microbiology to clinical work
Year: 2017


Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012


Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers
Source: Eur Respir J 2006; 28: Suppl. 50, 667s
Year: 2006

Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012


Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate as a fixed-dose combination in Japanese and Caucasian healthy subjects
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Pharmacokinetics of tiotropium administered by Respimat in adolescent asthma patients
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017


Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008


The pharmacokinetics of inhaled NVA237 in COPD patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012

Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans
Source: Eur Respir J 2006; 28: Suppl. 50, 661s
Year: 2006